We report on a prospective phase II trial of 32 patients who underwent unrelated-donor hematopoietic cell transplantation, with a tacrolimus, sirolimus and rabbit anti-thymoctye globulin GVHD prophylactic regimen. The primary study endpoint was incidence of grades II-IV acute (aGVHD), with 80% power to detect a 30% decrease compared with institutional historical controls. Median age at transplant was 60 (19-71). In total, 23 patients (72%) received reduced-intensity conditioning, whereas the remainder received full-intensity regimens. Median follow-up for surviving patients was 35 months (range: 21-49). The cumulative incidence of aGVHD was 37.3%, and the 2-year cumulative incidence of chronic GVHD was 63%. We observed thrombotic microangiopathy in seven patients (21.8%), one of whom also developed sinusoidal obstructive syndrome (SOS). Four of the 32 patients (12.5%) failed to engraft, and 3 of these 4 died. As a result, enrollment to this trial was closed before the targeted accrual of 60 patients. Two-year OS was 65.5% and EFS was 61.3%. Two-year cumulative incidence of relapse was 12.5% and non-relapse mortality (NRM) was 15.6%. NRM and aGVHD rates were lower than historical rates. However, the unexpectedly high incidence of graft failure requires caution in the design of future studies with this regimen.
INTRODUCTION
GVHD remains the leading cause of morbidity and mortality after allogeneic hematopoietic SCT (allo-HCT); both acute (aGVHD) and chronic (cGVHD) forms are associated with increased TRM. 1, 2 The novel combination of tacrolimus (TACRO) and sirolimus (SIR) for GVHD prophylaxis can decrease the rates of aGVHD and TRM. 3 In addition, SIR reduces CMV viremia 4 and the incidence/severity of oral mucositis. 5 Disadvantages of the TACRO/SIR regimen include a relatively high frequency 6 of cGVHD, and the association of SIR with an increased risk of thrombotic microangiopathy (TMA).
Since the introduction of G-CSF-mobilized PBSCs in 1989, 7 there has been a steady increase in the number of transplants conducted using this method for matched unrelated-donor (MUD) SCTs. 8 There has always been a concern that the incidence of GVHD in MUD PBSC transplants (PBSCTs) might be higher than for MUD BMTs due to the fact that the infused T-cell content can reach up to 15-fold higher for PBSCT than for BMT. 9 However, the literature is contradictory; some reports indicate a higher incidence of aGVHD in PBSCT, whereas others find a similar, or even slightly lower, incidence of aGVHD compared with MUD-BMT. [9] [10] [11] cGVHD incidence has been consistently found to be increased in PBSCT, 8, 11 which was confirmed in the recent randomized trial for MUD-PBSCT versus MUD-BMT. 12 We previously evaluated the combination of rabbit antithymocyte globulin (rATG) and CSA/MMF in 20 patients receiving unrelated-donor transplants (19 were PBSCT) using a reducedintensity conditioning (RIC) regimen of fludarabine (Flu) and melphalan (Mel). 13 The incidence of aGVHD grades II-IV was 75% and grades III-IV was 30%. Of interest, only 4/16 evaluable patients developed cGVHD, and only 2 patients required corticosteroid therapy. The 100-day non-relapse mortality (NRM) was 20%, with one death due to diffuse alveolar hemorrhage and three from complications of aGVHD. Frequent EBV reactivation was observed (9/20) , and was successfully treated with single-dose rituximab. This rate of EBV reactivation was higher than that reported by others, and may be related to a relatively high dose of rATG (7.5 versus 4-6 mg/kg).
With the increase in the number of MUD-PBSCT, the need for better GVHD prophylaxis becomes crucial. In an attempt to further improve GVHD prophylaxis and allo-HCT outcomes, we examined the novel combination of TACRO, SIR and rATG þ / À MTX.
MATERIALS AND METHODS

Study design
This City of Hope Institutional Review Board-approved phase II protocol (no. 06141) enrolled 32 patients who underwent unrelated-donor allo-HCT and were treated with the combination of TACRO, SIR and r-ATG as GVHD prophylaxis, with the option to add MTX for patients with a mismatched donor. The primary endpoints of the study were incidence/severity of aGVHD and cGVHD with safety assessments at day 30, 100 and 6 months post transplant. Secondary endpoints included time to platelet and absolute neutrophil recovery (engraftment), time to first hospital discharge following transplantation, incidence of infections (including CMV and EBV reactivation), incidence of TMA, NRM, OS and EFS at 1 year. aGVHD and cGVHD events were graded according to established criteria. 14, 15 Toxicities were graded according to the Common Terminology Criteria for Adverse Events (v3.0) 16 TMA was defined as the simultaneous occurrence of schistocytosis, increased lactate dehydrogenase and persistent thrombocytopenia (o50 000/mL). This trial was registered at http://www.clinical trials.gov (NCT00589563).
Eligibility criteria
Eligible patients were X3 years of age with a diagnosed hematological malignancy, who had a matched or mis-MUD, with KPS 460, Eastern Cooperative Oncology Group (ECOG) performance status p2 and adequate organ function (creatinine o1.3 mg/dL or creatinine clearance 470 mL/min, cardiac ejection fraction 445%, direct bilirubin, alanine aminotranferease and aspartate aminotransferase less than three times the upper limit of normal and forced vital capacity, forced expiratory volume in one second or diffusing capacity 445% predicted). 
Transplantation regimen
GVHD prophylaxis regimen
TACRO was administered at 0.02 mg/kg/day as a continuous i.v., beginning day À 3. Intravenous TACRO was discontinued once the patient started to eat, after which the drug was given orally at a dose of approximately three times the i.v. dose. TACRO trough levels were measured at least weekly during the first 100 days post transplant; the target blood level was 5-10 ng/mL. SIR dose for adults and patients who were 440 kg, was a 12 mg oral loading dose on day À 3 followed by SIR 4 mg daily beginning on day -2 (target serum level was 3-12 ng/mL). For pediatrics or patients o40 kg, SIR dose was administered at 3 mg/m 2 orally on day À 3, followed by 1 mg/m 2 orally as a single morning daily dose. Dosing of SIR was based on adjusted ideal body weight. rATG (Thymoglobulin, Genzyme Corporation, Cambridge, MA, USA) was administered at 0.5 mg/kg on day À 3, 1.5 mg/kg on day À 2 and 2.5 mg/kg on day À 1 or 0 (based on the timing of the stem cell infusion, within 24 h before transplant). In addition, patients with less than a 10/10 HLA match were eligible for addition of MTX at a dose of 5 mg/m 2 on days þ 1, þ 3 and þ 6.
Statistical analysis
OS and EFS were calculated using the Kaplan-Meier product-limit method. 17 EFS was defined as the time from stem cell infusion to death, relapse or progression, whichever occurred first. The cumulative incidence of aGVHD and cGVHD were estimated after taking into account the competing risk of death, relapse and graft failure. 18 The cumulative incidence for relapse was also computed treating a non-relapse death event as a competing risk. The study was designed to enroll 60 patients to compare the incidence of GVHD with our historical control group, using CSA/MMF as GVHD prophylaxis in unrelated-donor allo-HCT. The incidence of grades II-IV aGVHD in that setting was established as 63%. Assuming a two-sided type 1 error of 0.05, a sample size of 60 would have 80% power to detect a 30% reduction in the incidence of grades II-IV aGVHD. Table 1 summarizes patient characteristics and Table 2 summarizes study outcomes.
RESULTS
Patient characteristics
Thirty-two patients received unrelated-donor PBSC from September 2007 until July 2009. We did not reach the target of 60 enrolled patients, because accrual was halted after four patients experienced engraftment failure, three of whom died. Median follow-up for surviving patients was 35 months (range: 21-49).
Median age at transplant was 60 . About 47% of patients had intermediate/high-risk disease (patients in blast crisis, with relapsed or refractory disease, second CR, second chronic phase or refractory anemia with excess blast) at the time of transplant. Eighteen patients (56%) received stem cells from 10/10 matched donors and the remaining 14 patients (44%) received cells from donors with less than an 8/8 match. Eight patients with HLA mismatch had MTX added to their GVHD prophylaxis regimen. Twenty-three patients (72%) received RIC with Flu/Mel, whereas the remaining patients were conditioned with full-intensity regimens (FTBI/CY, FTBI/VP16). Engraftment Twenty-eight (87.5%) patients engrafted with an ANC 4500/mL and a median time to engraftment of 14.5 days. Four patients had graft failure; one with an antigen mismatch at HLA-A, two with an allele mismatch at HLA-A or B and another case with a 10/10 matched graft (Table 3) . Two of the four patients with graft failure received RIC whereas the other two had fully ablative conditioning. All patients received sufficient CD34 þ cell doses /kg). One graft failure patient recovered with autologous hematopoiesis and remained disease-free. One patient died of subsequent leukemia relapse and the other two patients died primarily of infections related to graft failure. No CMV, EBV, parvovirus 19 or HHV-6 infections were found by PCR in three cases (unique patient numbers 15, 21 and 30). Unique patient number 31 had HHV-6 infection but it occurred on day þ 57 post HCT, and was thus unlikely to be a contributing factor to graft rejection.
Survival outcomes After a median follow-up of 35 months, 19 patients were alive. Causes of death in 13 patients included disease progression (n ¼ 4), graft failure (n ¼ 2), infection (n ¼ 4), multi organ failure (n ¼ 1), refractory GVHD (N ¼ 1) and cGVHD (N ¼ 1). The probability of 2-year OS was 65.6% (95% confidence interval (CI): 53.7, 75.2; Figure 1a) , and EFS at 2-years was 61.3% (95% CI: 49.9, 70.8; Figure 1b ). Cumulative incidence of NRM was 9.4% (3.2, 27.5) at day 100, 12.5% (5.0, 31.3) at 1 year and 15.6% (7.0, 35.0) at 2 years (Figure 1c) . The competing risk of relapse incidence was 12.5% (5.0, 31.3) at 2 years (Figure 1d ).
GVHD
Grades II-IV aGVHD developed in 10 (36%) of 28 engrafted patients. Of these 10 patients, 9 had grade II and 1 had grade III disease. The cumulative incidence of aGVHD was 37.3% (22-62%) for all patients (Figure 2a) . cGVHD occurred in 21 of 23 evaluable patients (17 ¼ extensive, 4 ¼ limited); 9 patients were not evaluable for cGVHD due to engraftment failure, relapse or death before day 100. The cumulative incidence of cGVHD at 2 years was 63% (48-82%); the curve is depicted in Figure 2b . Of 19 patients who were alive, 13 patients were off all immunosuppressive medications at the last follow-up (median time 14.2 months, range: 6.1-31.2 months).
Treatment-related complications
We observed TMA in seven patients (21.8%), and one additional patient developed SOS. Thirteen (44.8%) of 29 patients at-risk (donor or recipient CMV þ ) developed CMV re-activation, and were treated with either i.v. ganciclovir or oral valganciclovir for induction, followed by maintenance doses of valganciclovir. Two patients developed CMV disease (one patient with CMV pneumonitis and one patient with CMV myocarditis, pneumonitis and colitis): both of them received treatment with foscarnet and/or ganciclovir. Seven patients (21.8%) developed EBV reactivation, of whom four patients received rituximab therapy. One patient developed EBV encephalitis and disseminated zoster and was treated with valganciclovir, IVIG and rituximab. Four patients experienced reactivation of both CMV and EBV.
Subset analyses
Flu/Mel Conditioning. Twenty-three patients (71.9%) received RIC with Flu and Mel, and their characteristics and outcomes were similar to the overall cohort. The cumulative incidences of aGVHD and cGVHD were not significantly different from the fully ablative (n ¼ 9) patients; aGVHD for RIC was 29.9% (95% CI: 15.2-58.9) and fully ablative was 75.0% (95% CI: 50.3-100.0), P ¼ 0.24. cGVHD at 2 years for RIC was 65.2% (95% CI: 48.4-87.9) and fully ablative was 55.6% (95% CI: 31.0-99.7), P ¼ 0.88.
MTX added to GVHD prophylaxis.
A total of eight patients also received MTX as part of their GVHD prophylaxis regimen. Similar 
DISCUSSION
This phase II study of GVHD prophylaxis with TACRO/SIR/rATG þ / À MTX for unrelated PBSCTs was designed to enroll 60 patients for comparing the incidence of aGVHD with our historical control group of patients treated with CSA/MMF/rATG as GVHD prophylaxis in unrelated donors. Unfortunately, the study was closed early due to a 12.5% incidence of engraftment failure. Despite this issue, for the 32 patients on study, the cumulative incidence of NRM at 2 years was only 15.6%. We observed a relatively low aGVHD rate of 37% for this highrisk cohort, notably, with only one case of grade III, and no grade IV aGVHD. The study was powered to detect a 30% reduction in the incidence of grades II-IV aGVHD compared with an institutional historical control of 63% at the time the protocol was written. As the study did not accrue 60 patients, we are unable to make any statistical claims. Final results from the historical control population (Flu/Mel conditioning with CSA/MMF/rATG GVHD prophylaxis 13 ) on Institutional Review Board protocol no. 03167 at this institution yielded a rate of 75% for grades II-IV aGVHD. Considering that the historical control patients were conditioned using only reduced-intensity regimens, the 37% rate of aGVHD in this study appears to be a substantial improvement. Among our 23 RIC study patients, the rate of aGvHD was only 29.9% (95% CI: 15.2-58.9) and compares more favorably. Alternatively, the 2-year cumulative incidence of cGVHD was high for this study, at 67%, compared with the historical control with CSA/MMF/ATG at 25%. 13 With the exception of higher graft failure and cGVHD rates, these data are comparable with our earlier study in sibling donor HCT using TACRO/SIR GVHD prophylaxis 6 (without ATG), in which we observed reduced grade III/IV aGVHD and low NRM. TMA, which is known to be associated with TACRO/SIR, had an incidence of 21.8%, which is comparable to previous reports. 6, 19 In addition, we compared our ATG results to historical data from a retrospective analysis (Institutional Review Board protocol no. 07076) of 63 patients who underwent MUD allogeneic HCT from 2005 to 2007 with Flu/Mel conditioning and TACRO/SIR GVHD prophylaxis (without ATG). The rate of aGVHD was higher in the historical TACRO/SIR population without ATG: 52.5% (40.1, 68.6) compared with 29.9% for the RIC subset analysis from this ATG study. Likewise, the historical cGVHD 2-year cumulative incidence was 86.3% (95% CI: 77.9-95.6) compared with 65.2% for the RIC subset in this ATG study. These data suggest that addition of rabbit ATG to the RIC regimen improved both aGVHD and cGVHD.
ATG has been added to some GVHD prophylaxis regimens resulting in a successful lowering of the incidence of GVHD. A trial by Ramsay et al. 20 in which 67 patients were randomized to receive MTX alone or with ATG and prednisone showed a significant decrease in the incidence of aGVHD (48% versus 21%) in favor of the ATG group. More recently, two randomized studies from the Italian group using two different doses of rATG (7.5 and 15 mg) with allo-HCT revealed that the higher dose of rATG resulted in less aGVHD compared with the lower dose (11% versus 50%). 21 However, the OS did not differ due to the negating effect of higher TRM secondary to increased infections with the higher ATG dose (30% versus 7%; P ¼ 0.02). Comparison of the effects of ATG in clinical trials is very difficult to assess owing to varying brands, dosages and timing relative to transplant. 22 The therapeutic effect can differ based on any of these factors.
Despite the fact that this cohort consists entirely of unrelated donors, many of whom had significant HLA mismatches, the aGVHD incidence of 37.3% was promising, and likely attributable to the addition of ATG. Unfortunately, we did not see an improvement in cGVHD rates. The results presented in the plenary session of the 2012 American Society of Hematology in San Diego indicate that for unrelated-allo-HCT donors there is a significant increase in cGVHD incidence in PBSC compared with BM recipients. 12 It is possible that this prophylaxis regimen would have better success in decreasing cGVHD in a population receiving BM grafts. Although the incidence of cGVHD was high in our cohort, 13 of 19 surviving patients were off all immunosuppressive drugs at the time of analysis, suggesting that the cGVHD was generally mildmoderate. The NIH cGVHD grading system 23 had not been adopted for this trial, and the classical limited/extensive grading system does not accurately reflect cGVHD severity.
The addition of ATG to TACRO and SIR has been tested recently with a significant reduction of aGVHD, however, this benefit was masked by increased SOS, which may be related to the type of conditioning regimen used. 24 In our study, the incidence of TMA was 21.8%, but only one patient developed SOS. The SOS patient had CML in blast crisis, and received FTBI/VP16 conditioning and GVHD prophylaxis without MTX.
We also noticed that CMV/EBV reactivation rates in this study were similar to other GVHD prophylaxis regimens. In a recent report, 450% of the patients at high risk, based on the serostatus of the donor and recipient, developed CMV reactivation. 25 The 44.8% rate of reactivation in our trial, despite the use of ATG, might be in part due to the incorporation of SIR in the GVHD prophylaxis. Some reports point out the inhibitory effect of SIR on the growth of human EBV-transformed B cells, which may in turn decrease the reactivation rate. 26 SIR was also found to be associated with reductions in CMV viremia. 4 The graft failure rate of 12.5% was much higher than our institutional 2% for unrelated donors. There were no obvious common features in the four patients with engraftment failure, except that three patients had myelodysplastic syndrome, possibly implicating previous transfusion requirements. We did not use G-CSF routinely after stem cell infusion, as do some institutions, and this could also be a factor. The combination of TACRO/SIR/rATG þ / À MTX may have been associated with intense in vivo T-cell depletion and/or myelosuppression, contributing to the graft failures. It is also possible that advanced disease status and HLA mismatch were contributing factors. We still recommend this r-ATG regimen to certain patients with a high degree of HLA mismatch, if after careful consideration the benefit is believed to outweigh the risk.
In summary, our phase II trial of the combination of TACRO/SIR/ rATG showed a reduced rate and severity of aGVHD and promising survival data compared with two institutional historical controls using TACRO/SIR and CSA/MMF/rATG. However, the unexpectedly high incidence of graft failures requires caution and very careful patient selection and design for future studies utilizing this combination GVHD prophylaxis regimen.
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